Core Insights - The article discusses a significant commercial battle in the beauty industry, particularly focusing on the competition between two major players, Huaxi Biological and Juzhi Biological, over the standards of recombinant collagen products [3][4][8] - The conflict highlights deeper issues within the biotechnology sector, such as the lack of research and development (R&D) investment and the prevalence of concept marketing over scientific validation [9][13][20] Group 1: Industry Competition - The battle over recombinant collagen standards has been ongoing for over a month, revealing a struggle for market share and consumer trust in the beauty sector [3][4] - The conflict was ignited by a report from beauty blogger "Big Mouth Doctor" questioning the amino acid content in Juzhi Biological's product, leading to public scrutiny [4][6] - Juzhi Biological's stock price fell by 37.12% from its peak on May 20 to June 23, resulting in a market value loss of 33.2 billion HKD, while Huaxi Biological's stock saw a slight increase of approximately 1.9% during the same period [8] Group 2: Research and Development Shortcomings - Juzhi Biological admitted to the limitations of its current testing methods, indicating a lack of adequate R&D investment, which was only 1.9% of its revenue in 2024, down from 2.1% in 2023 [9][10] - In contrast, Huaxi Biological and Jinbo Biological had R&D expense ratios of 8.68% and 10.89% respectively, showcasing a significant disparity in investment in innovation [9] - The article emphasizes the need for Juzhi Biological to enhance its R&D efforts to avoid future crises and to better respond to market challenges [10][13] Group 3: Industry Standards and Consumer Trust - The absence of national standards for recombinant collagen testing has led to confusion among consumers, as different companies use varying testing methods, resulting in inconsistent product quality [6][15] - The article argues that the reliance on concept marketing rather than scientific validation is unsustainable and can lead to significant reputational damage for companies [16][20] - The ongoing battle serves as a wake-up call for the industry to prioritize scientific rigor and consumer trust over short-term marketing gains [17][21]